MetaCap

Skye Bioscience (SKYE) vs Xenetic Biosciences (XBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xenetic Biosciences is the larger company by market cap ($3.3 million vs $3.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SKYE-57.58%XBIO-36.65%
+5%-28%-61%
Oct 7, 20261 yearNov 20, 2026
SKYE-58.58%XBIO-34.27%
+3%-29%-62%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SKYE versus XBIO key metrics
MetricSKYEXBIO
Share price$0.70$1.40
Market cap$3.10M$3.28M
1-day change-11.03%-9.09%
EPS (TTM)$-7.56$-1.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.98M
Revenue growth (YoY)—+19.04%
Net income (latest FY)$-55.92M$-2.68M
Operating margin—-95.23%
Net margin—-90.07%
52-week high$11.04$4.94
52-week low$0.484$1.25
Distance from 52-week high-93.66%-71.65%
Analyst consensusnone—
Avg. price target upside+9614.29%—
Average volume88.19K73.30K
Shares outstanding4.42M2.34M
Employees22
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Skye Bioscience

SKYE stock →

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

About Xenetic Biosciences

XBIO stock →

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

SKYE vs XBIO FAQ

Which is bigger, Skye Bioscience or Xenetic Biosciences?

Xenetic Biosciences (XBIO) is larger, with a market capitalization of $3.28M compared with $3.10M for Skye Bioscience (SKYE).

Are Skye Bioscience and Xenetic Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons